Join us in driving growth, innovation, and impact in the global healthcare market
Disrupting Gynecological Healthcare with AI, Automation & Theragnostic Innovation
Velquest Laboratories is building the next wave of MedTech innovation — combining AI-powered systems, intelligent biomaterials, and patented devices that address the $65B+ global women’s health and surgical care markets.
Backed by NIDHI PRAYAS, global PCT filings, and a pipeline of validated prototypes, Velquest is uniquely positioned to scale globally-relevant, affordable, and clinically impactful medical technologies.
6+ granted & pending patents across AI-based therapeutic devices, theragnostic gels, and surgical systems.
Addressable market in pelvic health, oncology recovery, and gynecological care is valued at INR 19,000+ Cr in India alone, with export potential to 50+ countries.
AI, IoT, and microfluidic integration across devices. Cutting-edge theragnostic gel tech in prototype stage with real-time diagnostics.
CE/ISO in 2024 → Clinical Trials in 2025 → Global Expansion in 2026. U.S. FDA & EU MDR pipeline initiated.
Year 3 breakeven with scale-ready production models. Projected Year 5 revenues: ₹19.5 Cr.
Licensing, clinical partnerships, and MedTech accelerators for rapid go-to-market across India, Europe, and MENA.
Cervical cancer is the second leading cause of cancer deaths in women worldwide.
Over 200,000 women undergo radiation therapy for gynecological conditions annually.
80%+ of patients suffer from post-treatment vaginal dryness, infections, or atrophy.
Few clinical-grade solutions exist that combine diagnostic + therapeutic support in a single platform.
With a structured market entry strategy and investment in clinical validation, we anticipate break-even in Year 3 and scalable market expansion by Year 5.:
| Year | Projected Sales (Units) | Revenue (INR Crores) | Profit Margin (INR Crores) | Cumulative Profit (INR Crores) |
|---|---|---|---|---|
| 1st Year | 5,000 | 3.25 | 2.00 | - 4.00 (Investment Phase) |
| 2nd Year | 10,000 | 6.50 | 4.00 | - 2.00 (Scaling Phase) |
| 3rd Year | 18,000 | 11.70 | 7.20 | Break-even Achieved |
| 4th Year | 25,000 | 16.25 | 10.00 | Profitable Growth |
| 5th Year | 30,000 | 19.50 | 12.00 | Scalability & Expansion |
With steady revenue growth and improving margins, Velquest Laboratories India is poised for long-term profitability and impact.
India’s government is committed to making healthcare affordable and accessible through initiatives like Ayushman Bharat and PLI (Production Linked Incentive) schemes. We align with these efforts by:
© VELQUEST LABORATORIES PVT LTD All Rights Reserved. Design by ONPAD